SCHEMBL3554389

SCHEMBL3554389

COc1ccccc1C(=O)Nc1ccccc1OCCOc1ccc(C(=O)O)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.57
RAB9A P51151 5/20 0.57
LMNA P02545 4/20 0.57
MAPT P10636 5/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
MAPK1 P28482 2/20 0.55
NPC1 O15118 2/20 0.55
TP53 P04637 1/20 0.55
TSHR P16473 3/20 0.54
HSD17B10 Q99714 2/20 0.54
GAA P10253 1/20 0.54
PLK1 P53350 1/20 0.53
PKM P14618 1/20 0.52
MEN1 O00255 4/20 0.52
ALDH1A1 P00352 1/20 0.51
KDM4E B2RXH2 2/20 0.51
HPGD P15428 1/20 0.51
ATM Q13315 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3561876 0.88 L3MBTL1 (0.54) KMT2ARAB9ALMNAMAPTL3MBTL1
SCHEMBL3557989 0.88 F10 (0.62) KMT2ARAB9ALMNAMAPTL3MBTL1
SCHEMBL3558462 0.87 PKM (0.54) KMT2ARAB9ALMNAMAPTL3MBTL1
SCHEMBL3563105 0.86 L3MBTL1 (0.60) KMT2ARAB9ALMNAL3MBTL1SMN1; SMN2
SCHEMBL3560773 0.86 PKM (0.52) KMT2ARAB9ALMNASMN1; SMN2NPC1
SCHEMBL3555876 0.86 CACNA1H (0.57) KMT2ARAB9ALMNAMAPTSMN1; SMN2
SCHEMBL27716594 0.85 RAB9A (0.74) KMT2ARAB9ALMNAMAPTL3MBTL1
SCHEMBL3559976 0.85 PKM (0.60) KMT2ARAB9ALMNAMAPTL3MBTL1
SCHEMBL3561367 0.83 PYGM (0.62) KMT2ARAB9ALMNAMAPTL3MBTL1
SCHEMBL3556306 0.81 RAB9A (0.56) KMT2ARAB9ALMNAL3MBTL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US claimed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US claimed
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US disclosed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes SLC5A1, ALDH7A1, ASS1 KMT2A 4045/4885RAB9A 4528/4885LMNA 2120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.